β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.

@article{Moraitou2011GlucocerebrosidaseGM,
  title={$\beta$-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.},
  author={M. Moraitou and G. Hadjigeorgiou and Ioannis Monopolis and E. Dardiotis and M. Bozi and D. Vassilatis and L. Vilageliu and D. Grinberg and G. Xiromerisiou and L. Stefanis and H. Michelakakis},
  journal={Molecular genetics and metabolism},
  year={2011},
  volume={104 1-2},
  pages={
          149-52
        }
}
An increasing number of clinical, neuropathological and experimental evidence linking Gaucher disease and a spectrum of synucleinopathies, including Parkinson's disease (PD) has emerged over the last decade. In particular, several studies, despite individual differences, have shown that mutations in the β-glucocerebrosidase gene (GBA) are a risk factor for PD. Recently a study from Northern Greece has shown a significant overrepresentation of such mutations only in patients with early onset PD… Expand
Mutations of glucocerebrosidase gene and susceptibility to Parkinson’s disease: An updated meta-analysis in a European population
TLDR
The study supported that GBA mutations were a risk factor for PD in the European population, and both L444P and N370S were associated with increased PD risk. Expand
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
TLDR
The identification of the SMPD1 p.L302P mutation as a strong risk factor for PD may further elucidate PD pathogenesis and the role of lysosomal pathways in disease development. Expand
Glucocerebrosidase and parkinsonism: lessons to learn
TLDR
Establishing the concept of GBA-related PD promoted a search for the pathogenic mechanisms through which GCase deficiency may influence pathogenesis of PD, suggesting that targeting the GCase–lysosomal pathway might be a rational approach for the development of neuroprotective drugs in PD. Expand
Understanding and managing parkinsonism in patients with glucocerebrosidase mutations
TLDR
The phenotypic presentation of patients with GBA1-associated parkinsonism is discussed and some treatment strategies will be discussed although treatment studies in this cohort are limited. Expand
The relationship between glucocerebrosidase mutations and Parkinson disease
TLDR
It is likely that, as in idiopathic PD, alpha‐synuclein accumulation, mitochondrial dysfunction, autophagic impairment, oxidative and endoplasmic reticulum stress may contribute to the development and progression of PD‐GBA1. Expand
An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson’s disease
TLDR
The results suggest that the studied mutations are quite rare in SPD patients, and the most frequent L444P mutation of the GBA gene may be associated with the development of EOPD in the Hungarian population. Expand
Mutations in GBA and risk of Parkinson’s disease: a meta-analysis based on 25 case-control studies
TLDR
Evidence is provided that both L444P and N370S were risk factors associated with increased PD susceptibility and when stratified by ethnicities, the associations varied among different ethnical origins. Expand
Beta-Glucocerebrosidase Gene Mutations P.Asn409Ser and P.Leu483Pro in Polish Patients with Parkinson's Disease
TLDR
It is yielded that carrier frequency of GBA mutation in polish population was comparable to other European populations p.Asn409Ser mutation dominates in patients with early onset PD disease. Expand
Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS
TLDR
It is implied that presence of mutant GCase leads to accumulation of parkin substrates like PARIS and ARTS, which may cause apoptotic death of cells, and this work aims to clarify this role and investigate its role in Parkinson's disease. Expand
The Association Between ß-Glucocerebrosidase Mutations and Parkinsonism
TLDR
Understanding the clinical association between GBA and PD, and the relationship between ß-glucocerebrosidase and α-synuclein, may enhance understanding of the pathogenesis of IPD, improve prognostication and treatment of GBA carriers with parkinsonism, and furthermore inform therapies for IPD not due to GBA mutations. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 38 REFERENCES
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
TLDR
It is demonstrated that GBA mutations are found in British subjects at a higher frequency than any other known Parkinson's disease gene and suggested that to date, this is the most common genetic factor identified for the disease. Expand
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece
TLDR
GBA mutations were significantly overrepresented in a subgroup of early onset PD patients, compared to controls, suggesting that GBA mutations may modify age of onset for PD. Expand
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
TLDR
Data collected demonstrate that there is a strong association between GBA mutations and Parkinson's disease, and those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were morelikely to have atypical clinical manifestations. Expand
The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism
TLDR
Evidence continues to support the role of GBA as a PD risk factor across different centers, synucleinopathies, and ethnicities, and further studies of the association between GD and parkinsonism will stimulate new insights into the pathophysiology of the two disorders. Expand
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.
TLDR
Genotype and clinical analyses on the largest homogeneous sample of European patients studied to date confirmed that GBA mutations are the most common genetic risk factor for PD, particularly in familial forms. Expand
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
TLDR
Data demonstrates that glucocerebrosidase can be an important component of α-synuclein-positive pathological inclusions in parkinsonian pathology and furthers the understanding of the lysosomal pathways that likely contribute to the formation and/or clearance of these protein aggregates. Expand
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal
TLDR
An increased number of Parkinson disease patients presenting mutations in GBA when compared to controls is found, which clearly suggest a role of glucocerebrosidase in the development of Parkinson Disease. Expand
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
TLDR
This study does not indicate increased susceptibility to PD in GBA mutations carriers in Norway, as previously reported in Ashkenazi Jews. Expand
Gaucher disease: frequency of the N370S mutation in the Greek population
TLDR
The true frequency of the N370S mutation is investigated by studying the genomic DNA purified from 1933 Guthrie cards, randomly sampled from the Greek National Neonatal Screening Program and it appears that there is a considerable underdiagnosis of N 370S homozygotes and an underestimation of the frequency of this mutation in the Greek population. Expand
Parkinson's disease: from monogenic forms to genetic susceptibility factors.
TLDR
Genome-wide associations and re-sequencing projects, together with gene-environment interaction studies, are expected to further define the causal role of genetic determinants in the pathogenesis of PD, and improve prevention and treatment. Expand
...
1
2
3
4
...